Using macrophage activation to augment immunotherapy of established tumours

Z. G. Fridlender*, A. Jassar, I. Mishalian, L. Cs Wang, V. Kapoor, G. Cheng, J. Sun, S. Singhal, L. Levy, S. M. Albelda

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Background: Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of immunotherapy.Methods:We and others have reported that 5,6-Dimethylxanthenone-4- acetic-acid (DMXAA, Vadimezan) has the ability to change TAM phenotypes, inducing a tumour microenvironment conducive to antitumour immune responses. We therefore combined DMXAA with active immunotherapies, and evaluated anti-tumour efficacy, immune cell phenotypes (flow cytometry), and tumour microenvironment (RT-PCR).Results:In several different murine models of immunotherapy for lung cancer, DMXAA-induced macrophage activation significantly augmented the therapeutic effects of immunotherapy. By increasing influx of neutrophils and anti-tumour (M1) macrophages to the tumour, DMXAA altered myeloid cell phenotypes, thus changing the intratumoural M2/non-M2 TAM immunoinhibitory ratio. It also altered the tumour microenvironment to be more pro-inflammatory. Modulating macrophages during immunotherapy resulted in increased numbers, activity, and antigen-specificity of intratumoural CD8 + T cells. Macrophage depletion reduced the effect of combining immunotherapy with macrophage activation, supporting the importance of TAMs in the combined effect.Conclusion:Modulating intratumoural macrophages dramatically augmented the effect of immunotherapy. Our observations suggest that addition of agents that activate TAMs to immunotherapy should be considered in future trials.

Original languageAmerican English
Pages (from-to)1288-1297
Number of pages10
JournalBritish Journal of Cancer
Volume108
Issue number6
DOIs
StatePublished - 2 Apr 2013
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by a National Cancer Institution Grant PO1 CA 66726 (to SMA) and by The Legacy Heritage fund program of the Israel Science foundation (Grant No. 1574/09 to ZGF). The project described was also partially supported by a grant from the Israel Lung Association and by Grant number 1 P30 ES013508-02 from the National Institute of Environmental Health Sciences (NIEHS), NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NIH.

Fingerprint

Dive into the research topics of 'Using macrophage activation to augment immunotherapy of established tumours'. Together they form a unique fingerprint.

Cite this